The presence of tumor-infiltrating T cells is associated with favorable patient outcomes, yet most pancreatic cancers are immunologically silent and resistant to currently available immunotherapies. Here we show using a syngeneic orthotopic implantation model of pancreatic cancer that Pik3ca regulates tumor immunogenicity. Genetic silencing of Pik3ca in 
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related death in the USA, with 44,330 deaths in 2018 and a five-year survival rate of only 8.5% [1] . Standard chemotherapies have little impact on PDAC patient survival, and even those patients who are suitable for surgical resection have only a 10% survival rate past five years [2] . Presence of tumorinfiltrating T cells is correlated with a better prognosis and increased survival of PDAC patients [3] [4] [5] [6] . Recognition of tumor cells by cytotoxic CD8 + T cells requires binding of the T cell receptor (TCR) to antigens presented on major histocompatibility complex class I (MHC I), which consists of a membrane-spanning heavy chain and β2 microglobulin (B2m). MHC I is expressed on the surface of all nucleated cells. Pancreatic cancer cell lines isolated from Kras G12D or Kras G12D ;Trp53 R172H mice [7] and many human pancreatic cancers and pancreatic cancer cell lines [8, 9] have low MHC I levels that might contribute to immune evasion. In addition to TCR activation, the co-receptor CD28 expressed on T cells is stimulated by CD80. Without CD80, activated T cells become anergic even in the presence of a presented antigen. CD80 is expressed mainly on the surface of professional antigen-presenting cells (APCs) but is sometimes detected at low levels on tumor cells. Upregulation of CD80 on tumor cells has been shown to render them more susceptible to lysis by T cells [10] [11] [12] .
More than 90% of PDACs have oncogenic mutations in the KRAS gene [13] .
Phosphoinositide 3-kinase (PI3K) is a critical downstream effector of KRAS. Class I PI3Ks are heterodimeric lipid kinases consisting of a regulatory subunit bound to one of four different p110 catalytic subunits (PIK3CA (also called p110α), PIK3CB, PIK3CD or PIK3CG). In normal cells, PI3Ks regulate proliferation, survival, and differentiation. Upon activation, PI3Ks catalyze the conversion of phosphatidylinositol-4,5-bisphosphate to phosphatidylinositol-3,4,5-trisphosphate (PIP 3 ). PIP 3 then recruits downstream effectors such as the protein kinase AKT to the cell membrane, aiding in its phosphorylation and activation [14] . The PI3K-AKT signaling cascade is 5 among the most frequently dysregulated and hence extensively studied pathways in human cancers [15] [16] [17] .
PI3Ks in pancreatic cells and in immune cells have been shown to affect pancreatic tumorigenesis and cancer growth. Oncogenic KRAS G12D signals through PIK3CA, but not PIK3CB, to induce acinar-to-ductal metaplasia that is required for pancreatic tumor formation [18] , and the catalytic activity of PIK3CA is required for this tumorigenic process [19] . It is not yet known if PIK3CA is also required for the growth and progression of established PDAC in vivo. Moreover, PIK3CA's role in cancer immune surveillance has not been studied. Signaling by PIK3CG and PIK3CD in leukocytes, but not in tumor cells, can affect how the immune system responds to tumors in murine models, including pancreatic cancer [20, 21] . Small molecules that inhibit all PI3K isoforms have little effect or transient suppressive effects on PDAC growth in mouse models (reviewed in [22] and [23] ). However, these drugs inhibit PI3Ks in both the tumor cells and immune cells, so the results of systemic inhibitor studies should be interpreted with caution.
In this study, we examined the function of PIK3CA in a pancreatic cancer cell line derived from mice expressing KRAS G12D and TRP53 R172H [24, 25] . We show that cells lacking PIK3CA are viable in vitro but are cleared by tumor-infiltrating T cells when implanted in the pancreas of immunocompetent mice. The susceptibility of these tumors to immunosurveillance is due at least in part to increased expression of MHC I and CD80 on the tumor cell surface. 6 
RESULTS

Pik3ca in Implanted KPC Cells Promotes Tumor Progression and Lethality
Both Pik3ca and Egfr have been shown to be required for KRAS G12D -induced pancreatic tumorigenesis [18, 19, 26] . To investigate the possible roles of Pik3ca and Egfr in pancreatic cancer progression, we used the FC1245 pancreatic cancer cell line that was isolated from a Kras LSL-G12D/+ ;Trp53 LSL-R172H/+ ;Pdx1-Cre mouse in the C57BL/6 (B6) genetic background [25] .
We first produced a parental cell line that stably expresses luciferase (referred to as wildtype (WT) KPC). We extracted genomic DNA from WT KPC cells to sequence exon 1 of the Kras gene and confirmed that the cells have a G-D mutation at codon 12. We did not detect the WT allele of the Kras gene ( Supplementary Fig. S1 ). Such loss of the WT Kras allele is common in cell lines derived from both genetically engineered mouse models and patients with PDAC and other cancers [27] [28] [29] [30] . Loss of WT KRAS is frequently associated with amplification in the mutant allele and has been shown to increase the aggressiveness and migration of PDAC and other cancers [27-31]. We then used CRISPR/Cas9 to produce KPC cell lines that lack either Pik3ca or Egfr (referred to as αKO or EgfrKO, respectively). Complete loss of PIK3CA or EGFR was confirmed by western blotting (Supplementary Fig. S2A ). Immunoblotting and reverse phase protein array (RPPA) analysis also revealed changes in signaling due to ablation of Pik3ca or Egfr. In particular, there was a large decrease in AKT phosphorylation at S473 and T308 in αKO cells as compared to WT cells, while EgfrKO cells had higher levels of AKT phosphorylation than WT cells (Supplementary Fig. S2 ). WT and EgfrKO KPC cells proliferated at similar rates in standard 2D culture conditions, whereas αKO cells proliferated at about half the rate of WT cells (Fig. 1A) . The percentage of cells stained with annexin V in each culture was not significantly different, indicating that the decreased proliferation rate of αKO KPC cells is not due to increased apoptosis (Fig. 1B) . When grown under 3D culture conditions, all three cell lines formed compact spheroid colonies (Fig. 1C) , indicating a capacity for anchorage-independent growth. 7 We next studied the growth of these cell lines in vivo. WT, αΚΟ, or EgfrKO cells were implanted in the head of the pancreas of syngeneic B6 mice, and tumor growth was monitored longitudinally by IVIS imaging. As expected, WT cells grew rapidly and formed large tumors (Fig.   1D ). Median tumor volume quantified as total luminescence flux showed a 29.6-fold increase from day 1 to day 14 (Fig. 1E) . Tumors formed by EgfrKO cells grew at a significantly slower rate ( Fig.   1D and E). Mice implanted with WT or EgfrKO cells died 2 to 3 weeks after implantation, with a median survival of 16 days or 17 days, respectively (Fig. 1F) . In contrast, tumors formed by implanted αKO cells showed an increase in median size from day 1 to day 7, and then the tumors regressed so that the luciferase signal was undetectable in 16 of 17 mice on day 14 ( Fig. 1D and E). By day 21, the luciferase signal was undetectable in all 17 mice (data not shown). All B6 mice implanted with αKO cells were alive 80 days later (Fig. 1F) . Some of these convalescent animals have been kept for up to 18 months after tumor implantation without any overt signs of illness.
Implantation of B6 mice with another clone of αKO cells yielded similar results ( Supplementary   Fig. S3 ). At necropsy, mice implanted with WT or EgfrKO cells exhibited large pancreatic tumors and metastases to the peritoneum, liver, diaphragm, and lungs. H&E staining of pancreatic sections confirmed the presence of large tumors with a strong desmoplastic response (Fig. 1G) .
Some of the mice implanted with αKO cells were euthanized after 6 months: no abnormal lesions in any of the organs were seen by visual inspection, and no tumors were found in pancreatic sections of these animals (Fig. 1G) .
Regression of αKO KPC Tumors is Linked to T Cell Infiltration
To investigate if a host immune response might be responsible for the regression of αKO tumors in our mouse model, we implanted WT, αKO, or EgfrKO tumor cells in the pancreas of B6 mice and sacrificed the animals 10 days later. H&E staining of pancreatic sections from all three groups showed substantial areas of normal pancreas interspersed with tumors ( Fig. 2A) .
Immunohistochemistry showed that αKO tumors were infiltrated with large numbers of CD3 + , 8 CD4 + , and CD8 + cells (e.g., T cells) ( Fig. 2A and B) . Similar to most human pancreatic tumors, WT and EgfrKO tumors were associated with peri-tumoral T cells, but few T cells were seen infiltrating the tumors ( Fig. 2A and B) . We did not observe a significant difference in the number of F4/80 + macrophages infiltrating the tumors in the three groups ( Fig. 2A and B) .
To test if tumor-infiltrating T cells are responsible for tumor regression, we injected B6 mice with neutralizing antibodies to deplete CD4 + and CD8 + T cells. Depletion of T cells was confirmed by flow cytometry (Supplementary Fig. S4A ). We then implanted these mice with αKO cells. IVIS imaging showed that αKO tumors grew in these mice. The average fold-change in tumor volume from day 1 to day 21 was 65.7 ( Fig. 2C ). All mice that received neutralizing antibodies died due to tumor growth ( Fig. 2D and E) . As expected, the control mouse that did not receive injections of neutralizing antibodies showed complete tumor regression (Fig. 2E) . To determine the specific subtype of T cells involved in tumor regression, we implanted αKO cells in immunocompromised mice lacking CD4 + or CD8 + T cells (referred to as CD4KO and CD8KO).
αKO tumors did not regress in CD4KO or CD8KO mice and all of the animals died from tumor growth ( Fig. 2C and D and Supplementary Fig. S4B ). Tumor growth was slower in the CD4KO mice, and they survived longer than the CD8KO animals (median survival of 47 days vs. 37 days, respectively). Further, CD4KO and CD8KO mice survived significantly longer than B6 mice depleted of CD4 + and CD8 + T cells by neutralizing antibodies (median survival of 29 days) (Fig.   2D ). Immunohistochemistry showed a decrease in the number of tumor-infiltrating CD8 + T cells in CD4KO mice and fewer tumor-infiltrating CD4 + T cells in CD8KO mice as compared to tumors in B6 animals ( Fig. 2E and F) . These results suggest that both CD4 + and CD8 + T cells are essential and that they cooperate with each other to infiltrate αKO tumors and cause tumor regression.
Adoptive T Cell Transfer Protects SCID Mice from αKO KPC Tumors
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We next investigated if T cells from a convalescent B6 mouse (implanted with αKO cells and recovered for 6 months; see Fig. 1G ) can target and kill αKO cells implanted in mice with severe combined immune deficiency (SCID) that lack functional T and B cells. We first implanted αKO cells in the head of the pancreas of a control group of SCID mice. The tumors grew rapidly and killed all of the animals ( Fig. 3A-C) . A second group of SCID mice was implanted with αKO cells one day after receiving an adoptive transfer of CD90.2 + T cells enriched from the spleens of convalescent mice. The αKO tumors regressed in these animals ( Fig. 3A and B) and all of the mice survived for >80 days without overt signs of illness (Fig. 3C) . H&E-stained pancreatic sections showed that the control group of SCID mice had large tumors with little normal tissue, while mice that received T cells had completely normal pancreas 4 months after implantation (Fig.   3D ).
We next asked if adoptive T cell transfer is an effective treatment for established αKO tumors. Two groups of SCID mice were implanted with αKO cells in the pancreas. After determining tumor size 4 days later by IVIS imaging (Fig. 3E and F, t = 0), one group of animals was given 14.25 million T cells from convalescent mice and the second group was treated with 6.38 million T cells. Mice that received 14.25 million T cells showed complete tumor regression after one week (Fig. 3E) and all of the animals survived for >10 weeks. In mice that received fewer T cells, the tumors regressed but started growing again after 3-4 weeks (Fig. 3F) . We collected pancreata from the animals treated for 5 weeks with 6.38 million T cells and examined pancreatic sections by immunohistochemistry. Some of the αKO tumors were infiltrated by CD4 + and CD8 + T cells (top panels, Fig. 3G ), whereas others from the same mouse were scarcely infiltrated with T cells (bottom panels, Fig. 3G ). These results suggest that T cells from mice previously exposed to the αKO tumor can be used to induce tumor regression in another animal as long as the number of T cells relative to tumor cells is adequate. Indeed, the significance of T cell number and the time of adoptive T cell transfer to eradicate tumors has been reported [32] .
Pik3ca-dependent Suppression of MHC I and CD80 Levels Contributes to Immune Evasion of WT KPC Tumors
We first analyzed RNAseqV2 and RPPA data from The Cancer Genome Atlas (TCGA) to check for a correlation between the effectors of the PI3K signaling pathway and CD80 and MHC I. We assessed the mRNA levels of CD80 and B2m in 180 PDAC patients and observed a positive correlation with PTEN mRNA expression. Patients that showed high PTEN expression also had high levels of B2m and CD80 mRNA. Conversely, patients with low PTEN mRNA had low mRNA levels of CD80 and B2m ( Fig. 5A and B) . In addition, analysis of the RPPA data showed that pAKT S473 expression was inversely correlated with B2m mRNA levels in PDAC patients ( Implanted αKO/CD80KO tumors grew larger over the first week and then regressed in every animal ( Fig. 4D and Supplementary Fig. S6 ). All of the animals implanted with αKO/CD80KO cells survived >100 days (Fig. 4E ). In contrast, 7 of 8 mice implanted with αKO/CD80KO+shB2m cells still had detectable pancreatic tumors at week 7 ( Fig. 4D and Supplementary Fig. S6 ), and all these animals eventually died from tumor progression (Fig. 4E) . Examination of pancreatic tissue from αKO/shB2m or αKO/CD80KO+shB2m mice that succumbed to tumor progression showed large tumors that were devoid of infiltrating CD4 + or CD8 + T cells ( 
AKT Acting Downstream of PIK3CA is Responsible for Immune Evasion of KPC cells
Because AKT activity is significantly higher in WT KPC cells than in αKO cells (Supplementary Fig. S8B ). When implanted in the pancreas of B6 mice, the αKO-Cont tumors grew over the first 7 days and then regressed, and all of the mice lived for >70 days (Fig. 5C-E) .
In contrast, the αKO-caAkt cells grew rapidly, formed large tumors, and killed all of the animals ( Fig. 5C-E) . Mice that died from implanted αKO-caAkt cells had large pancreatic tumors and extensive metastases to the liver, lungs, and colon. Some mice also had metastases to the diaphragm and peritoneum. Pancreatic sections showed tumors devoid of intra-tumoral CD4 + or CD8 + T cells, although T cells were present in tissue surrounding the tumors (Fig. 5F and G) .
These results are similar to what we observed with WT KPC cells implanted in B6 mice (see Fig.   1D -F). Mice implanted with αKO-Cont cells were sacrificed 71 days after implantation. H&E-stained pancreatic sections showed no abnormalities (Fig. 5F ). These results suggest that PIK3CA-AKT signaling mediates immune evasion in WT KPC cells. 14 
DISCUSSION
Pancreatic tumors in patients are well known for their ability to exclude T cells [35] [36] [37] , and limited T cell infiltration is also a prominent feature of pancreatic tumors in Kras LSL-G12D/+ ;Trp53 LSL-R172H/+ ;Pdx1-Cre mice [35, 38, 39] . The presence of tumor-infiltrating cytotoxic T cells is correlated with increased survival of pancreatic cancer patients [3] [4] [5] [6] . The salient finding of this study is that Although PIK3CG is expressed mainly in hematopoietic cells, it was reported to be present at high levels in human pancreatic cancer tissue. Downregulation of PIK3CG slightly slowed the proliferation of PDAC cell lines in culture [58] . A subsequent study showed that genetic ablation or systemic pharmacological inhibition of PIK3CG led to activation of T cells and slower PDAC growth in vivo [21] . These antitumor effects were attributed to suppression of PIK3CG in macrophages leading to suppression of cytotoxic T cells and not due to decreased PIK3CG in tumor cells. Genetic or pharmacologic downregulation of PIK3CG altered the transcriptional program of tumor-infiltrating macrophages to promote cytotoxic T cell infiltration of pancreatic 17 tumors, thus extending survival of the mice [21, 59, 60] . However, unlike ablation of Pik3ca in KPC tumor cells, all of the animals with downregulated PIK3CG eventually died from pancreatic cancer progression [21] . PIK3CD is expressed mainly in leukocytes and is critical for the differentiation and function of effector T cells and CD4 + regulatory T cells (Tregs) [61] .
Suppression of PIK3CD in Tregs protected host mice from a broad range of transplanted cancers [20] , but it is unclear if downregulation of PIK3CD slowed pancreatic cancer growth in vivo [62] .
Several immunotherapeutic strategies are being investigated to promote infiltration of T cells into pancreatic tumors [10] . Our results indicate that PIK3CA may be a potential drug target to increase T cell immunogenicity of pancreatic cancer. Treatment with a pan-isoform PI3K inhibitor did not reduce the tumor volume of KPC cells or patient-derived xenografts implanted in mice [63] . Based on our current understanding, systemic pharmacological inhibition of all PI3K isoforms should enhance the immunogenicity of the pancreatic tumors by upregulating MHC I and CD80, but inhibitory effects on cytotoxic T cells will negate these beneficial changes. (Addgene plasmid #53583) was a gift from Heng Zhao [66] ). 48 hours after infection, cells expressing EGFP were collected using FACS; mutant Akt1 expression was confirmed by western blotting. All murine cell lines were cultured in DMEM media containing 10% fetal bovine serum and 1% penicillin/streptomycin at 37 C and 5% CO 2 . Human pancreatic cancer cell lines Panc1, HPAF-II, and PSN1 were purchased from ATCC and cultured using recommended conditions. Patient-derived human pancreatic cancer cell lines were previously described and cultured as recommended [67] .
2D Cell Proliferation Assay: 5,000 cells were plated in triplicate in a 6-well plate. On days 1 through 4, cells were trypsinized, mixed with an equal volume of trypan blue, and counted using the Countess II automated cell counter (Life Technologies). Cell number was plotted against time using GraphPad Prism 7. 3D Cell Culture: 3D cultures used previously described protocols [68] . Briefly, 1,000 cells in DMEM containing 10% FBS were mixed with methylcellulose stock solution to a final concentration of 0.24% methylcellulose. Cells were cultured by the hanging drop method on the lid of a 96-well plate. To prevent evaporation, PBS was added to the plate. The plates were incubated at 37 C in a 5% CO 2 atmosphere. The cells were imaged on day 5 using brightfield microscopy with a 40X objective.
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Immunoblotting: Cell lysates were prepared in RIPA buffer (50 mM HEPES, pH 7.4, 10 mM sodium pyrophosphate, 50 mM NaCl, 50 mM NaF, 5 mM EDTA, 1 mM sodium orthovanadate, 0.25% sodium deoxycholate, 1% NP40, 1 mM PMSF, and protease inhibitor cocktail (Sigma P8340)) and cleared by centrifugation at 4 C. Cell proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes by semi-dry transfer, and the membranes were incubated with primary antibodies in Tris-buffered saline plus 0.1% Tween 20. After incubation in HRP-linked secondary antibody followed by ECL reagent (Western Lightning Plus-ECL (PerkinElmer) or SuperSignal West Femto (ThermoFisher Scientific), signals were detected using a FluorChem E imager (ProteinSimple). To detect multiple proteins on the same membrane, HRP was inactivated by incubating membranes in 30% H 2 O 2 for 30 minutes [69] , or the membranes were stripped for 30 min at 50 C in 62.5 mM Tris, pH 6.7, 2% SDS, and 100 mM 2-mercaptoethanol prior to reprobing with another antibody.
Reverse Phase Protein Array (RPPA): Cells were plated in duplicate in a 6-well plate, washed 2 times in PBS, and lysed in RPPA lysis buffer (1% Triton X-100, 50 mM HEPES, pH 7.4, 150 mM NaCl, 1.5 mM MgCl 2 , 1 mM EGTA, 100 mM NaF, 10 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 10% glycerol, 1 mM PMSF, and protease inhibitor cocktail). Protein concentration was adjusted to 1.5 μg/μl in SDS sample buffer (40% glycerol, 8% SDS, 0.25 M Tris-HCl, pH 6.8, and 1.43 M 2-mercaptoethanol). The samples were sent to M.D. Anderson Cancer Center Core Facility for RPPA analysis. Briefly, cell lysates were serially diluted two-fold for 5 dilutions (from undiluted to 1:16 dilution) and arrayed on nitrocellulose-coated slides in an 11x11 format. Samples were probed with antibodies using a tyramide-based signal amplification approach and visualized by DAB colorimetric reaction. Slides were scanned on a flatbed scanner to produce 16-bit tiff images. Spots from tiff images were identified and the density was quantified 21 by Array-Pro Analyzer. Normalized Log2 values were median-centered and used for heatmap generation using GraphPad Prism v7. Mice were anesthetized with a mixture of 100 mg/kg ketamine and 10 mg/kg xylazine. The abdomen was shaved and swabbed with a sterile alcohol pad followed by povidone-iodide scrub.
Mice
A small vertical incision was made over the left lateral abdominal area, to the left of the spleen.
The head of the pancreas attached to the duodenum was located. Using a sterile Hamilton syringe with a 27 gauge needle, 0.5 million cells in 30 μl PBS were injected into the head of the pancreas.
The injection site was pressed with a sterile cotton swab to prevent leakage. The abdominal and skin incisions were closed with 5-0 silk black braided sutures. The mice were given an intraperitoneal injection of 2 mg/kg Ketorolac immediately after surgery. To monitor tumor growth, the animals were injected intraperitoneally with 100 mg/kg RediJect D-Luciferin (PerkinElmer) and imaged on the IVIS Lumina III imaging system (Xenogen). Data were analyzed using Living Image v4.3.1 software.
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Survival Studies: Mice implanted with tumor cells were monitored by IVIS imaging every week for tumor growth. Death, weight loss of  15% body weight, or inability to move were considered as endpoints at which surviving animals were euthanized.
Neutralizing Antibody Experiment: B6 mice were injected intraperitoneally with 500 μg of neutralizing antibodies against CD4 (BioXcell, Clone GK1. 
